Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Amosartan XQ vs Co-administration in Healthy Males
NCT04322266Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlodipine + losartan + ezetimibe + rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Amlodipine at Day 15, Area Under the Plasma Concentration-Time Curve to the Last Measurable Concentration for Amlodipine at Day 15 and 8 more. Started Dec 2018; status: completed.
02
Drugs
amlodipine + losartan + ezetimibe + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04322266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322266.